La Jolla Pharmaceutical Company (LJPC)
Stock Price:
$3.56 USD
-0.29 (-7.53%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed
After-hours: $3.60 +0.04 (1.12%) Oct 28, 7:53 PM
Key Info
| Market Cap |
97.41M |
| Revenue (ttm) |
26.35M |
| Net Income (ttm) |
-78.59M |
| Shares Out |
27.36M |
| EPS (ttm) |
-2.89 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$3.56 |
| Previous Close |
$3.85 |
| Change ($) |
-0.29 |
| Change (%) |
-7.53% |
| Day's Open |
3.80 |
| Day's Range |
3.55 - 3.81 |
| Day's Volume |
387,285 |
| 52-Week Range |
2.30 - 9.38 |
More Stats
| Market Cap |
97.41M |
| Enterprise Value |
50.39M |
| Earnings Date (est) |
Mar 8, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
27.36M |
| Float |
26.96M |
| EPS (basic) |
-2.90 |
| EPS (diluted) |
-2.89 |
| FCF / Share |
-1.97 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.40M |
| Short Ratio |
8.63 |
| Short % of Float |
12.61% |
| Beta |
2.53 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
3.70 |
| PB Ratio |
n/a |
| Revenue |
26.35M |
| Operating Income |
-74.84M |
| Net Income |
-78.59M |
| Free Cash Flow |
-53.74M |
| Net Cash |
47.02M |
| Net Cash / Share |
1.72 |
| Gross Margin |
78.41% |
| Operating Margin |
-284.00% |
| Profit Margin |
-298.20% |
| FCF Margin |
-203.94% |
| ROA |
-32.56% |
| ROE |
-686.50% |
| ROIC |
-145.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (3)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$10.67*
(199.72% upside)
Low
4.00
Current: $3.56
High
20.00
Target: 10.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 23.05 | 10.06 | - | 0.62 | 1.06 | - | - | - | - | - |
| Revenue Growth | 129.26% | - | - | -41.72% | - | - | - | - | - | - |
| Gross Profit | 20.66 | 8.41 | - | 0.62 | 1.06 | - | - | - | - | - |
| Operating Income | -110 | -194 | -115 | -78.37 | -41.97 | -21.34 | -17.94 | -10.74 | -2.27 | -3.93 |
| Net Income | -117 | -199 | -115 | -78.19 | -41.91 | -21.31 | -17.94 | -7.74 | -11.55 | -3.76 |
| Shares Outstanding | 27.11 | 25.42 | 21.22 | 17.23 | 15.65 | 10.67 | 1.54 | 0.20 | 0.01 | 0.02 |
| Earnings Per Share | -4.30 | -7.85 | -5.41 | -4.54 | -2.68 | -2.00 | -12.16 | -41.77 | -1,579.50 | -250.00 |
| Operating Cash Flow | -84.95 | -152 | -85.08 | -58.71 | -25.18 | -12.88 | -4.73 | -2.14 | -1.83 | -3.39 |
| Capital Expenditures | -0.70 | -2.34 | -9.19 | -2.22 | -1.82 | -0.26 | -0.04 | - | - | - |
| Free Cash Flow | -85.65 | -155 | -94.28 | -60.93 | -27.00 | -13.14 | -4.78 | -2.14 | -1.83 | -3.39 |
| Cash & Equivalents | 88.73 | 174 | 91.82 | 65.93 | 127 | 48.59 | 8.67 | 3.41 | 5.04 | 6.87 |
| Total Debt | 26.48 | - | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 62.25 | 174 | 91.82 | 65.93 | 127 | 48.59 | 8.67 | 3.41 | 5.04 | 6.87 |
| Assets | 132 | 204 | 120 | 70.80 | 129 | 50.54 | 8.75 | 3.43 | 5.10 | 6.93 |
| Liabilities | 188 | 168 | 31.34 | 9.76 | 4.82 | 2.08 | 1.09 | 0.22 | 20.66 | 6.45 |
| Book Value | -55.99 | 35.92 | 88.20 | 61.04 | 125 | 48.46 | 7.65 | 3.21 | -15.56 | 0.48 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
La Jolla Pharmaceutical Company |
| Country |
United States |
| Employees |
90 |
| CEO |
Larry Edwards |
Stock Information
| Ticker Symbol |
LJPC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: LJPC |
| IPO Date |
June 3, 1994 |
Description
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is headquartered in San Diego, California.